header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-MRPHLNO-060407-3
Morpholino Name: MO2-etv2
Target: etv2 (1)
Previous Names: EtsrpMO (1), MO2-ets1b, MOetsrp (1)

Add new Alias

Alias
Attribution

Attributions for Alias: {{control.newAlias}}

{{pub.zdbID}}

Delete Alias:

(Including Attributions)
Sequence:
5' - CACTGAGTCCTTATTTCACTATATC - 3'
   
Select Sequence Analysis Tool

  (Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.)
TARGET LOCATION
No data available
CONSTRUCTS WITH SEQUENCES FROM MO2-etv2 No data available
GENE EXPRESSION
Gene expression in Wild Types + MO2-etv2
Expressed Gene Anatomy Figures
cdh5 Fig. 5 from Moore et al., 2018
clec14a Fig. 4 with image from Sumanas et al., 2006
dusp5 Fig. 4 with image from Sumanas et al., 2006
etv2 Fig. 4 with imageFig. 5 with image from Sumanas et al., 2006
fli1a Fig. 6 with image from Davis et al., 2018
Fig. 5 with image from Sumanas et al., 2006
flt4 Fig. 6 with image from Davis et al., 2018
Fig. 4 with image from Sumanas et al., 2006
gata1a Fig. 4 with image from Sumanas et al., 2006
gpr182 Fig. 4 with image from Sumanas et al., 2006
kdrl Fig. 4 with image from Liu et al., 2008
Fig. 7 with image from Sumanas et al., 2006
lyve1b Fig. 6 with image from Davis et al., 2018
sox7 Fig. S2 from Herpers et al., 2008
sox18 Fig. S2 from Herpers et al., 2008
spi1a Fig. 4 from Bukrinsky et al., 2009
spi1b Fig. 4 from Bukrinsky et al., 2009
tal1 Fig. 4 with imageFig. 5 with image from Sumanas et al., 2006
PHENOTYPE
Phenotype resulting from MO2-etv2
Phenotype of all Fish created by or utilizing MO2-etv2
Phenotype Fish Conditions Figures
posterior lateral mesoderm morphology, abnormal AB + MO2-etv2 standard conditions Fig. 4 with image from Liu et al., 2008
embryonic hemopoiesis disrupted, abnormal AB + MO2-etv2 standard conditions Fig. 4 with image from Liu et al., 2008
myeloid cell differentiation disrupted, abnormal WT + MO1-etv2 + MO2-etv2 standard conditions Fig. 2 from Sumanas et al., 2008
endothelial cell cdh5 expression absent, abnormal WT + MO1-etv2 + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
endothelial cell absent, abnormal WT + MO1-etv2 + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
blood vasculature morphology, abnormal WT + MO2-etv2 standard conditions Fig. S2 from Herpers et al., 2008
posterior caudal vein flt4 expression decreased amount, abnormal WT + MO2-etv2 control Fig. 6 with image from Davis et al., 2018
posterior caudal vein lyve1b expression decreased amount, abnormal WT + MO2-etv2 control Fig. 6 with image from Davis et al., 2018
blood vessel morphogenesis disrupted, abnormal WT + MO2-etv2 standard conditions Fig. S2 from Herpers et al., 2008
regulation of myeloid leukocyte differentiation disrupted, abnormal WT + MO2-etv2 standard conditions Fig. 4 from Bukrinsky et al., 2009
whole organism neoplasm has fewer parts of type blood vessel, abnormal ci5Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 7 from Baltrunaite et al., 2017
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal ci6Tg + MO1-etv2 + MO2-etv2 control Fig. 2 from Craig et al., 2015
blood vessel development disrupted, abnormal s843Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 3 with image from Chou et al., 2013
blood vasculature lacks parts or has fewer parts of type blood vessel, abnormal s843Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. S5 from Reischauer et al., 2016
dorsal aorta absent, abnormal s843Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 3 with image from Chou et al., 2013
caudal vein plexus EGFP expression decreased amount, abnormal s843Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. S5 from Reischauer et al., 2016
intersegmental vessel EGFP expression absent, abnormal s843Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. S5 from Reischauer et al., 2016
interrenal primordium bilateral, abnormal y1Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 2 with image from Chou et al., 2010
vascular endothelium mislocalised, abnormal y1Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 2 with image from Chou et al., 2010
posterior cardinal vein absent, abnormal y1Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 2 with image from Chou et al., 2010
vasculogenesis process quality, abnormal y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
intersegmental vessel absent, abnormal y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
dorsal aorta absent, abnormal y1Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 2 with image from Chou et al., 2010
interrenal primordium left side unfused from interrenal primordium right side, abnormal y1Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 2 with image from Chou et al., 2010
dorsal aorta decreased size, abnormal y1Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 2 with image from Chou et al., 2010
axial vasculature apoptotic process increased process quality, abnormal y1Tg + MO1-etv2 + MO2-etv2 control Fig. 6 from Craig et al., 2015
intersegmental vessel spatial pattern, abnormal y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
dorsal aorta absent, abnormal y1Tg + MO2-etv2 control Fig. 4 with image from Qiu et al., 2016
whole organism neoplasm lacks all parts of type angiogenic sprout, abnormal y1Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 5 from Baltrunaite et al., 2017
whole organism neoplasm decreased size, abnormal y1Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 5 from Baltrunaite et al., 2017
whole organism neoplasm EGFP expression decreased amount, abnormal y1Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 5 from Baltrunaite et al., 2017
vasculature EGFP expression increased amount, abnormal y1Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 5 from Baltrunaite et al., 2017
thoracic duct EGFP expression absent, abnormal y1Tg + MO2-etv2 standard conditions Fig. 4 with image from Davis et al., 2018
posterior cardinal vein absent, abnormal y1Tg + MO2-etv2 control Fig. 4 with image from Qiu et al., 2016
thoracic duct absent, abnormal y1Tg + MO2-etv2 standard conditions Fig. 4 with image from Davis et al., 2018
vasculature EGFP expression increased amount, abnormal y1Tg + MO2-etv2 cancer xenotransplantation Fig. 5 from Baltrunaite et al., 2017
intestine decreased size, abnormal zf346Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 3 with image from Chou et al., 2013
dorsal aorta absent, abnormal zf346Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 3 with image from Chou et al., 2013
blood vessel development disrupted, abnormal zf346Tg + MO1-etv2 + MO2-etv2 standard conditions Fig. 3 with image from Chou et al., 2013
vascular lymphangioblast absent, abnormal ci5Tg; y1Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
thoracic duct EGFP expression absent, abnormal ci5Tg; y1Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
trunk vasculature morphology, abnormal ci5Tg; y1Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
vascular lymphangioblast EGFP expression absent, abnormal ci5Tg; y1Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
lymphangiogenesis decreased occurrence, abnormal ci5Tg; y1Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
thoracic duct absent, abnormal ci5Tg; y1Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
vascular lymphangioblast decreased amount, abnormal nim5Tg ; nkuasgfp1aTg + MO2-etv2 standard conditions Fig. 5 with image from Davis et al., 2018
blood cell decreased amount, abnormal tsu2013Tg ; sd2Tg + MO2-etv2 control Fig. 4 with image from Qiu et al., 2016
thoracic duct TagRFP expression absent, abnormal y1Tg ; nim5Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
trunk vasculature morphology, abnormal y1Tg ; nim5Tg + MO2-etv2 standard conditions Fig. 3 with image from Davis et al., 2018
thoracic duct absent, abnormal y1Tg ; nim5Tg + MO2-etv2 control Fig. 3 with image from Davis et al., 2018
endothelial cell cdh5 expression absent, abnormal gfi1aaqmc551Gt/qmc551Gt + MO2-etv2 standard conditions Fig. 5 from Moore et al., 2018
endothelial cell absent, abnormal WT + MO1-etv2 + MO1-gna13a + MO1-gna13b + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
endothelial cell cdh5 expression absent, abnormal WT + MO1-etv2 + MO1-gna13a + MO1-gna13b + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
myocardium fused with myocardium, ameliorated WT + MO1-etv2 + MO1-gna13a + MO1-gna13b + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
myocardial precursor cardioblast migration to the midline involved in heart field formation occurrence, ameliorated WT + MO1-etv2 + MO1-gna13a + MO1-gna13b + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
intersegmental vessel sprouting angiogenesis arrested, abnormal fli1btpl50Gt/+; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
vasculogenesis process quality, abnormal fli1btpl50Gt/+; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
intersegmental vessel absent, abnormal fli1btpl50Gt/+; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
axial vasculature apoptotic process increased process quality, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 6 from Craig et al., 2015
intersegmental vessel sprouting angiogenesis arrested, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
axial vasculature malformed, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
vasculogenesis process quality, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
axial vasculature vasculogenesis process quality, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
intersegmental vessel absent, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO1-etv2 + MO2-etv2 control Fig. 3 from Craig et al., 2015
whole organism neoplasm EGFP expression decreased amount, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 6 from Baltrunaite et al., 2017
whole organism neoplasm lacks all parts of type angiogenic sprout, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 6 from Baltrunaite et al., 2017
whole organism neoplasm lacks parts or has fewer parts of type blood vessel, abnormal fli1btpl50Gt/tpl50Gt; y1Tg + MO2-etv2 ultraviolet light, cancer xenotransplantation Fig. 6 from Baltrunaite et al., 2017
endothelial cell absent, abnormal fb9Tg ; y1Tg + MO1-etv2 + MO1-gna13a + MO1-gna13b + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
endothelial cell EGFP expression absent, abnormal fb9Tg ; y1Tg + MO1-etv2 + MO1-gna13a + MO1-gna13b + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
myocardial precursor cardioblast migration to the midline involved in heart field formation occurrence, ameliorated fb9Tg ; y1Tg + MO1-etv2 + MO1-gna13a + MO1-gna13b + MO2-etv2 standard conditions Fig. 8 with image from Xie et al., 2016
OTHER MO2-etv2 MORPHOLINO PAGES No links to external sites
CITATIONS (32)